• Best practices
  • Best practice: mVacciNation improves vaccine stock issues
Best practice

mVacciNation improves vaccine stock issues




A successfully scaled-up mobile technology platform that tracks vaccine stock data in remote locations.


Mozambique, Nigeria and Tanzania


Support health workers to improve vaccine stock management and data efficiency in vaccination records.


It’s estimated that up to a fifth of children worldwide do not receive basic vaccines, despite advances in funding and availability.

It’s estimated that up to a fifth of children worldwide do not receive basic vaccines, despite advances in funding and availability.

GSK's mVacciNation platform uses mobile phones to track vaccine stock. ©Jenny Cozins

GSK’s mVacciNation programme uses the proliferation of mobile phones in Africa to establish innovative ways to increase vaccination and improve supply. The programme operates a health intervention to record newborn and childhood vaccinations electronically, and addresses needs in the supply chain, specifically in demand forecasting and real-time stock visibility.

Through mVaccinNation, mobile phones are used for three purposes: to improve stock management through a stock visibility system; to establish an electronic medical record of vaccinations and improve data efficiency; and to remind caregivers when children are due for vaccination, and encourage them to complete a regimen.

How does this initiative improve child vaccination?
Initially, GSK and its partners, including Vodafone, ran a one-year pilot in Mozambique, in collaboration with the country’s ministry of health, combining expertise in healthcare, vaccines and technology. Through mobile technology, it aimed to increase the proportion of children covered by vaccination by up to 10%. In 2014, the Index recognised the pilot in Mozambique as an innovation. Then in 2016, the programme earned Index scale-up credit through its expansion in Mozambique. More than 100,000 children in Mozambique have been reached and over 400,000 vaccinations provided.

The partners have rolled out mVacciNation in two more countries, Tanzania and Nigeria, in 2015 and 2017, respectively, with funding from the Human Development Innovation Fund (HDIF), Gavi and USAID.

What makes this a best practice?
The scale-ups have begun to show success as well, with evidence of mothers returning to healthcare facilities for vaccinations due to SMS reminders from the mVacciNation system. By replicating the programme and showing it can scale successfully, GSK has created an example of best practice in supply-chain capacity building.

This initiative meets all standards of good practice applicable to supply chain initiatives. It addresses local needs, works in partnership, is guided by clear goals and objectives, aims to make long-term and sustainable improvements, and measures progress and outcomes. For example, it uses clearly defined key performance indicators and deliverables to measure the progress its implementation partners are making.

Before pilots began in Tanzania and Nigeria, GSK commissioned independent parties to conduct a comprehensive baseline study in each country. When these pilots end, GSK plans to carry out end line assessments to demonstrate proof of concept.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.